Amarin Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa(R) and FDA Approved MARINE

Amarin Announces Notification of Patent Allowance for U.S. Application
13/623,450 Related to Vascepa(R) and FDA Approved MARINE Indication

Strengthens Positioning of Vascepa for Exclusivity Into 2030

BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 13, 2012 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of Notice of Allowance for
U.S. Patent Application Serial Number 13/623,450. This application includes
claims intended to protect the Vascepa^® (icosapent ethyl) indication approved
by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE
clinical trial results.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.

The claims in this allowed application cover a method of use relating to
Vascepa's MARINE indication. Specifically, the allowed independent claim
covers use of highly pure icosapent ethyl, or EPA, including Vascepa, in
lowering triglycerides regardless of the drug's effect on LDL-C levels.

"This allowance is significant in that it would broaden our currently issued
MARINE method of use claims to cover the use of Vascepa (and other highly pure
EPA formulations) without regard to LDL-C levels," stated Joseph Zakrzewski,
Chairman and CEO of Amarin. "The issuance of this Notice of Allowance
represents yet another significant step toward Amarin's goal of protecting the
commercial potential of Vascepa to beyond 2030 through patent protection,
regulatory exclusivity and trade secrets and by taking advantage of
manufacturing barriers to entry."

This application is part of an expanding patent portfolio for Amarin with 11
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States, including the application for Amarin's MARINE method of use
patent in Europe for which Amarin has announced receipt of an Intention to
Grant letter.

The 13/623,450 Notice of Allowance has not yet been posted on the USPTO public
PAIR website.Amarinhas posted this Notice of Allowance and related claims in
the Press Release section of its corporate website.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book, Amarin's
plan to protect the commercial potential of Vascepa, and the future status of
pending patent applications. These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties. Among the
factors that could cause actual results to differ materially from those
described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials and related regulatory approvals. A
further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

CONTACT: Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo